On JSC “Grindeks” financial results for nine months of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
On JSC “Grindeks” financial results for nine months of 2014

Riga, Latvia, 2014-11-28 16:37 CET (GLOBE NEWSWIRE) --  

Today, on 28 November, the JSC “Grindeks” submitted the non-audited consolidated financial statements for nine months of 2014 to “NASDAQ OMX Riga”. Non-audited financial results indicate that turnover of the Group in the nine months of 2014 was 63.1 million euros and has decreased by 17.3 million euros or 21.5% in comparison to the nine months of 2013. While the Group’s net profit, attributable to shareholders of the parent company, was 3.7 million euros in the nine months of 2014 and has decreased by 4 million euros or 52.4% in comparison to the nine months of 2013. Gross profit margin in the nine months of 2014 was 58.3% while net profit margin was 5.8%. In the nine months of 2014 the Group’s production was exported to 57 countries worldwide, a total of 59.7 million euros which is 16.4 million euros or 21.5% less than in the nine months of 2013.

The turnover ratio of the nine months of 2014 in comparison to the same period of the last year has been influenced by a number of key factors – geopolitical situation in Russia and Ukraine, which led to the devaluation of the national currency, as well as a wholesale warehouse balance optimization. Because of these factors, the forecast that the performance in Russia will improve in the second half year has not reached the expected result, while the decrease in net profit was due to an increased investment in research and development of two strategic projects. In cooperation with scientists of Latvia the project of inhibitor of cardio protective agent – GBB hydroxyls with an original structure – chemical and preclinical pharmacological efficiency studies have concluded, which is an important step in creating a new medical product. The other project is registration of a drug Mildronate® in China, where the 3rd phase of clinical trial for this medication is now being held.

Sales volume of the final dosage forms of “Grindeks” in the nine months of 2014 was 55.6 million euros and has decreased by 15.7 million euros or 22% in comparison to the nine months of 2013. The main final dosage forms markets are Russia, other CIS countries, Georgia and the Baltic States. The sales amount in Russia, other CIS countries and Georgia reached 45.2 million euros in the nine months of 2014, which is by 16 million euros or 26.2% less than in the nine months of 2013. The highest increase, compared to the nine months of 2013 is shown in Belarus +51%, Azerbaijan +36%, Armenia +31% and Turkmenistan +29%. In its turn, turnover of the final dosage forms in the Baltic States and other European countries was 10.4 million euros, which is by 0.3 million euros or 3.4% more than in the nine months of 2013. In the nine months of 2014 “Grindeks” has begun export of final dosage forms to several new markets – Great Britain, Finland, Slovakia, Spain, the Netherlands and Portugal. Cooperation with Tunisia that was launched last year is successfully ongoing and shows +78% increase in comparison to the nine months of the last year, and Vietnam where sales amount has increased by 12.1. The turnover in the nine months of 2014 has increased by 76% in markets outside the CIS and the Baltic States in comparison to the nine months of the last year. The highest growth in comparison to the nine months of 2013 is in Czech Republic +32%.

In the nine months of 2014, sales of active pharmaceutical ingredients reached 7.4 million euros which is by 1.7 million euros or 18.7% less than in the nine months of 2013. Main markets of “Grindeks” active pharmaceutical ingredients in the nine months of 2014 are the Netherlands, Germany, Canada, USA, France, Ireland and Japan. The most required active pharmaceutical ingredients of “Grindeks” are Zopiclone, Oxytocin, Ftorafur, Droperidol, Xylazine, Medetomodine, Detomidine and Ursodeoxycholic acid .

JSC “Grindeks” Chairman of the Board Juris Bundulis: “Business activities in the high risk markets is causing additional challenge to the company, however, “Grindeks” continues to work on product development, carries out new intentions and enters new markets. The pharmaceutical industry has its own specifics - the results cannot be achieved as quickly as we would like and we have to aim towards the long term development. As “Grindeks” is a long-term growth oriented company, we are working on the business risk mitigation and diversification step by step, as well as business development in new markets and in order to reduce our dependence on situation in a specific region, we sign contracts with new clients of existing markets. Positive factors that indicate a positive trend and will improve performance of "Grindeks" in the future are the steady demand of “Grindeks” products and registration of new products in different markets.”

About “Grindeks”

“Grindeks” is the leading pharmaceutical company in the Baltic States. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. “Grindeks” Group consists of 4 subsidiary companies in Latvia, Estonia and Russia; representative offices are opened in 13 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. The portfolio of “Grindeks” products consists of successful combination of branded products and generic medications – including brand products Mildronate® and Ftorafur®, as well as more than 100 effective and safe medications. Currently “Grindeks” manufactures 25 active pharmaceutical ingredients.

Products of the company are exported to 59 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S.

To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing 70.7 million euros over the years.

JSC “Grindeks” shares are listed on the Official List of “NASDAQ OMX Riga”. Major shareholders of JSC “Grindeks” are Kirovs Lipmans – 33.29%, “AB.LV Private Equity fund 2010” – 22.66%, Anna Lipmane – 16.69%, “Swedbank” AS Clients Account (nominee account) – 10.47%.

More information about the company – www.grindeks.lv/en/
Follow “Grindeks”:
Twitter.com/AS_Grindeks ; Youtube.com/GrindeksLV

         Further information:
         Laila Klavina
         Head of the Communications Department, JSC “Grindeks”
         Phones: (+371) 67083370, (+371) 29256012
         Fax: (+371) 67083505
         laila.klavina@grindeks.lv

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 95

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 86

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 102

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 121

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 75

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 111

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 72

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 139

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 119

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading

Top 5 Most Recently Viewed Articles

Ollie's Bargain Outlet Raises Over $1.3 Million for Charity

Updated Category News Views 216

Ollie's Bargain Outlet Makes a Difference this Holiday Season Ollie's Bargain Outlet recently announced an impressive fundraising effort, raising over $1.3 million for the Marine Toys for Tots Program. This initiative highlights the company's commitment to giving back to the community during the holiday season. From early November to early December, participating Ollie's...

Continue Reading
Navigating the Integer Holdings Corporation Class Action Concerns

Updated Category News Views 147

Your Rights as an Investor in Integer Holdings Corporation If you've invested in Integer Holdings Corporation (NYSE: ITGR), you might be feeling concerned about recent developments. The company, known for its role in cardiac rhythm management and cardiovascular product manufacturing, is currently under scrutiny due to allegations that it misled investors regarding the...

Continue Reading
Indochino Welcomes Sean Wrenn as New Vice President of Retail

Updated Category News Views 163

Indochino Welcomes Sean Wrenn as New Vice President of Retail INDOCHINO, the leader in made to measure apparel, has appointed Sean Wrenn as the new Vice President of Retail Sales and Operations. With over two decades of retail experience, Sean is set to enhance the company’s operations and customer engagement. Sean Wrenn's Background and Expertise Sean Wrenn joins...

Continue Reading
Innovative Partnership Enhances Efficiency in Dairy Processing

Updated Category News Views 200

Collaboration to Boost Dairy Processing Efficiency In an exciting development within the dairy processing sector, CADDi, a renowned provider of digital solutions for manufacturers, has teamed up with Dairy Conveyor Corporation (DCC Automation). This collaboration marks a significant step towards optimizing supply chains and fostering better communication across DCC's...

Continue Reading
Celebrating Food and Beverage Excellence in the Middle East

Updated Category News Views 171

Celebrating Excellence in Food and Beverage The Middle East Food & Beverage Excellence Awards is an annual event that brings together the best in the industry, turning the spotlight on the remarkable achievements of food and beverage professionals. Last night, at the stunning JW Marriott Marina, industry leaders in the Middle East gathered for an unforgettable evening...

Continue Reading